<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We report a single center experience of 222 patients (pts) less than 18 years old transplanted from 1973 to 1987 </plain></SENT>
<SENT sid="1" pm="."><plain>The median age was 11 years (1-18) </plain></SENT>
<SENT sid="2" pm="."><plain>The donor was a monozygotic twin (9 pts), an HLA-id sibling (193 pts), an HLA-id, parent (9 pts), a mismatched related donor (9 pts) and a matched unrelated donor (1 pt) </plain></SENT>
<SENT sid="3" pm="."><plain>Ninety-six pts were transplanted for SAA </plain></SENT>
<SENT sid="4" pm="."><plain>Conditioning varied with time but the majority (59 pts) received CY 150 mg/kg and 6 Gy TAI </plain></SENT>
<SENT sid="5" pm="."><plain>The long term actuarial survival is 66% with a median follow-up of 3 years </plain></SENT>
<SENT sid="6" pm="."><plain>The group who received CY 200 mg/kg and MTX had a 33% long term survival (LTS) </plain></SENT>
<SENT sid="7" pm="."><plain><z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GVH</z:e> was the main complication with 40% <z:hpo ids='HP_0011009'>acute</z:hpo> and 37% <z:hpo ids='HP_0011010'>chronic</z:hpo> GVHD </plain></SENT>
<SENT sid="8" pm="."><plain><z:hpo ids='HP_0011010'>Chronic</z:hpo> GVHD tended to improve with time after 2 to 4 years of evolution </plain></SENT>
<SENT sid="9" pm="."><plain>Ninety pts were transplanted for <z:hpo ids='HP_0001909'>leukemia</z:hpo> (35 AML, 45 ALL and 11 CGL), 20 pts were in relapse </plain></SENT>
<SENT sid="10" pm="."><plain>Pts in CR had a LTS of 40%, in pts in relapse, it was 12% </plain></SENT>
<SENT sid="11" pm="."><plain>The main causes of <z:hpo ids='HP_0011420'>death</z:hpo> were: <z:hpo ids='HP_0006515'>interstitial pneumonitis</z:hpo> (30%), relapse (27%), <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GVH</z:e> (15%) </plain></SENT>
<SENT sid="12" pm="."><plain>Thirty-five pts were transplanted for constitutional disease: Fanconi <z:hpo ids='HP_0001903'>anemia</z:hpo> (FA) (26 pts), <z:mp ids='MP_0009563'>Dyskeratosis</z:mp> congenita (2 pts), <z:e sem="disease" ids="C1260899" disease_type="Disease or Syndrome" abbrv="BDS">Blackfan-Diamond</z:e> <z:e sem="disease" ids="C0877221" disease_type="Disease or Syndrome" abbrv="">erythroblastopenia</z:e> (2 pts), <z:e sem="disease" ids="C0235604" disease_type="Disease or Syndrome" abbrv="">Glanzmann</z:e> <z:hpo ids='HP_0004807'>thrombasthenia</z:hpo> (1 pt), <z:hpo ids='HP_0011002'>osteopetrosis</z:hpo> (1 pt) and <z:e sem="disease" ids="C0017205" disease_type="Disease or Syndrome" abbrv="">Gaucher's disease</z:e> (1 pt) </plain></SENT>
<SENT sid="13" pm="."><plain>In FA, the LTS is 70% with a CY 20 mg/kg, 5 Gy TAI regimen </plain></SENT>
<SENT sid="14" pm="."><plain>In <z:hpo ids='HP_0000001'>all</z:hpo> disease categories, we did not find any influence of donor's sex on <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GVH</z:e> and survival.(ABSTRACT TRUNCATED AT 250 WORDS) </plain></SENT>
</text></document>